87 related articles for article (PubMed ID: 25744425)
1. Combination of bevacizumab and acyclic retinoid inhibits the growth of hepatocellular carcinoma xenografts.
Kubota M; Shimizu M; Baba A; Ohno T; Kochi T; Shirakami Y; Moriwaki H
J Nutr Sci Vitaminol (Tokyo); 2014; 60(5):357-62. PubMed ID: 25744425
[TBL] [Abstract][Full Text] [Related]
2. Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Sakai H; Yasuda Y; Tsurumi H; Moriwaki H
Cancer Lett; 2009 Nov; 285(2):210-7. PubMed ID: 19520494
[TBL] [Abstract][Full Text] [Related]
3. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells.
Tatebe H; Shimizu M; Shirakami Y; Tsurumi H; Moriwaki H
Clin Cancer Res; 2008 May; 14(9):2806-12. PubMed ID: 18451248
[TBL] [Abstract][Full Text] [Related]
4. Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.
Baba A; Shimizu M; Ohno T; Shirakami Y; Kubota M; Kochi T; Terakura D; Tsurumi H; Moriwaki H
BMC Cancer; 2013 Oct; 13():465. PubMed ID: 24103747
[TBL] [Abstract][Full Text] [Related]
5. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
6. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Katsura Y; Wada H; Murakami M; Akita H; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S517-26. PubMed ID: 23508585
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
8. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
9. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
Kanamori T; Shimizu M; Okuno M; Matsushima-Nishiwaki R; Tsurumi H; Kojima S; Moriwaki H
Cancer Sci; 2007 Mar; 98(3):431-7. PubMed ID: 17270033
[TBL] [Abstract][Full Text] [Related]
10. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
12. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
[TBL] [Abstract][Full Text] [Related]
13. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells.
Obora A; Shiratori Y; Okuno M; Adachi S; Takano Y; Matsushima-Nishiwaki R; Yasuda I; Yamada Y; Akita K; Sano T; Shimada J; Kojima S; Okano Y; Friedman SL; Moriwaki H
Hepatology; 2002 Nov; 36(5):1115-24. PubMed ID: 12395321
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.
Guo XL; Li D; Sun K; Wang J; Liu Y; Song JR; Zhao QD; Zhang SS; Deng WJ; Zhao X; Wu MC; Wei LX
J Mol Med (Berl); 2013 Apr; 91(4):473-83. PubMed ID: 23052483
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
[TBL] [Abstract][Full Text] [Related]
16. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
17. Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways.
Shao RX; Otsuka M; Kato N; Taniguchi H; Hoshida Y; Moriyama M; Kawabe T; Omata M
Gastroenterology; 2005 Jan; 128(1):86-95. PubMed ID: 15633126
[TBL] [Abstract][Full Text] [Related]
18. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
19. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
20. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
Esposito V; Verdina A; Manente L; Spugnini EP; Viglietti R; Parrella R; Pagliano P; Parrella G; Galati R; De Luca A; Baldi A; Montesarchio V; Chirianni A
J Cell Physiol; 2013 Mar; 228(3):640-5. PubMed ID: 22886568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]